Laurus Labs shares jump 4% on Motilal Oswal 'buy' call, 30% upside seen
C
CNBC TV18•20-03-2026, 13:54
Laurus Labs shares jump 4% on Motilal Oswal 'buy' call, 30% upside seen
•Laurus Labs shares gained over 4% after Motilal Oswal reiterated its 'buy' rating.
•Motilal Oswal projects a 30% upside, setting a target price of ₹1,280 per share.
•The company is strengthening its CDMO position with global innovator pharma companies and securing formulation-level contracts for patented products.
•Laurus has built advanced technology capabilities in peptides, cell and gene therapy, fermentation, and continuous manufacturing.
•Ongoing capacity expansion, diversification into animal health and crop science, and a JV with KRKA for formulations business are expected to drive growth.
